WS 009A

endothelin receptor antagonist; from Streptomyces sp. No. 89009; structure given in first source

Also Known As:

WS-009A; WS009A; L-Cysteine, N-acetyl-S-(4,4a,5,6,7,12,12a,12b-octahydro-4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxobenz(a)anthracen-6a(1H)-yl)-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Chen, W: 1 article (09/2001)
2.	Yang, X: 1 article (09/2001)

1.	Right Ventricular Hypertrophy 09/01/2001 - "There were no haemodynamic and right ventricular hypertrophy differences between WS009A group and control group. "
2.	Pulmonary Hypertension 09/01/2001 - "To investigate the effect of ETA receptor antagonist, WS009A, on the pathogenesis of hypoxic pulmonary hypertension in rats. " 09/01/2001 - "[The effect of ETA receptor antagonist WS009A on the pathogenesis of hypoxic pulmonary hypertension in rats]." 09/01/2001 - "The ETA receptor antagonist, WS009A, attenuates the pulmonary vascular wall remodelling and the pulmonary hypertension induced by chronic hypoxia."
3.	Hypoxia (Hypoxemia) 09/01/2001 - "In the course of chronic hypoxia, rats were treated with WS009A (10 mg/kg) by a siliastic catheter inserted in the left external jugular vein. " 09/01/2001 - "The ETA receptor antagonist, WS009A, attenuates the pulmonary vascular wall remodelling and the pulmonary hypertension induced by chronic hypoxia."

1.	Catheters